检索结果 - Manuel Hidalgo

Refine Results
  1. 1
    New insights into pancreatic cancer biology

    New insights into pancreatic cancer biology 由 Manuel Hidalgo

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy

    Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy 由 Manuel Hidalgo, S. Gail Eckhardt

    出版 2001
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  3. 3
    Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer

    Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer 由 Antonio Jimeno, Manuel Hidalgo

    出版 2006
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  4. 4
    Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment

    Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment 由 Viktor Grünwald, Manuel Hidalgo

    出版 2003
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  5. 5
    New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists

    New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists 由 Hetty E. Carraway, Manuel Hidalgo

    出版 2004
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  6. 6
    Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping

    Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping 由 José Luís Royo, Manuel Hidalgo, Agustı́n Ruiz

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Matrix Metalloproteinase-2 Contributes to Cancer Cell Migration on Collagen

    Matrix Metalloproteinase-2 Contributes to Cancer Cell Migration on Collagen 由 Xiaoping Xu, Yao Wang, Zhihua Chen, Mark D. Sternlicht, Manuel Hidalgo, Bjorn Steffensen

    出版 2005
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

    Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the He... 由 Denis Soulières, Neil Senzer, Everett E. Vokes, Manuel Hidalgo, Sanjiv S. Agarwala, Lillian L. Siu

    出版 2003
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer

    Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer 由 Sreedhar Venkannagari, Warren Fiskus, Karissa Peth, Peter Atadja, Manuel Hidalgo, Anirban Maitra, Kapil N. Bhalla

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations

    A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations 由 Bárbara Angulo, Elena García-García, Rebeca Martínez, Ana Suárez‐Gauthier, Esther Conde, Manuel Hidalgo, Fernando López‐Ríos

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Effect of human immunodeficiency virus on blood-brain barrier integrity and function: an update

    Effect of human immunodeficiency virus on blood-brain barrier integrity and function: an update 由 Venkata Atluri, Manuel Hidalgo, Thangavel Samikkannu, Kesava Rao Venkata Kurapati, Rahul Dev Jayant, Vidya Sagar, Madhavan Nair

    出版 2015
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  12. 12
    Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway

    Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway 由 Linda A. deGraffenried, Letitia C. Fulcher, William E. Friedrichs, Viktor Grünwald, Ratna B. Ray, Manuel Hidalgo

    出版 2004
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors

    CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors 由 Jing Li, Mats O. Karlsson, Julie R. Brahmer, Avery Spitz, Ming Zhao, Manuel Hidalgo, Sharyn D. Baker

    出版 2006
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Genome-wide profiling at methylated promoters in pancreatic adenocarcinoma

    Genome-wide profiling at methylated promoters in pancreatic adenocarcinoma 由 Noriyuki Omura, Chung–Pin Li, Ang Li, Seung‐Mo Hong, Kimberly Walter, Antonio Jimeno, Manuel Hidalgo, Michael Goggins

    出版 2008
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms

    Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms 由 Michele Cioffi, Sara Trabulo, Manuel Hidalgo, Eithne Costello, William Greenhalf, Mert Erkan, Jörg Kleeff, Bruno Sáinz, Christopher Heeschen

    出版 2015
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model

    A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model 由 N.V. Rajeshkumar, Zeshaan A. Rasheed, Elena García-García, Fernando López‐Ríos, Kôsaku Fujiwara, William Matsui, Manuel Hidalgo

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500)

    A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induct... 由 Kishan J. Pandya, Suzanne E. Dahlberg, Manuel Hidalgo, Roger B. Cohen, Martin Lee, Joan H. Schiller, David H. Johnson

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents

    Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents 由 Antonio Jimeno, Belén Rubio‐Viqueira, María L. Amador, Darin Oppenheimer, Nadia Bouraoud, Peter Kulesza, Valeria Sebastiani, Anirban Maitra, Manuel Hidalgo

    出版 2005
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients

    Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients 由 Jing Li, George Cusatis, Julie R. Brahmer, Alex Sparreboom, Robert W. Robey, Susan E. Bates, Manuel Hidalgo, Sharyn D. Baker

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Metformin Targets the Metabolic Achilles Heel of Human Pancreatic Cancer Stem Cells

    Metformin Targets the Metabolic Achilles Heel of Human Pancreatic Cancer Stem Cells 由 Enza Lonardo, Michele Cioffi, Patricia Sancho, Yolanda Sanchez-Ripoll, Sara Trabulo, Jorge Navarro‐Dorado, Anamaria Balic, Manuel Hidalgo, Christopher Heeschen

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: